Skip to main content

Table 1 DM patients’ demographic data and biochemical parameters

From: Myostatin and markers of bone metabolism in dermatomyositis

 

DM patients

n = 20

Control group n = 20/ Normative values

Age

66 [55; 76]

61 [56; 68]

BMI

26 [23; 30]

26 [23; 30]

Disease duration

6.5 [4.25; 12.5]

Treatment

 GC alone

4

 GC + immunosuppressionc

4

 IVIG alone

2

 IVIG+GC/±immunosuppressiond

5

 IVIG+immunosuppressiond

5

 CRP [mg/dl]

0.3 [0.1; 0.6]

< 0.5a

 CK [U/l]

133 [63; 173]

<  170a

 Aldolase [U/l]

3.8 [2.5; 5.4]

0–7.6a

 Ca [mmol/l]

2.3 [2.3; 2.4]

2.4 [2.3; 2.6]b

 Phosphate [mmol/l]

1.04 [0.94; 1.19]

1.20 [1.08; 1.51]b

 Creatinine [mg/dl]

0.74 [0.64; 0.87]

0.86 [0.79; 1.01]b

 PTH [pg/ml]

43.2 [33.0; 69.5]

36.0 [15.7; 44.9]

 25OHD [nmol/l]

66.7 [50.4; 87.0]

40.7 [26.0; 59.5]b

 BAP [U/l]

8.8 [5.9; 12.4]

5.2–24.4a

 OC [ng/ml]

18.8 [10.0; 27.8]

22.3 [15.1; 32.0]

 P1NP [ng/ml]

42.0 [29.5; 80.5]

37.7 [28.8; 74.5]

 CTX [ng/ml]

0.22 [0.11; 0.50]

0.22 [0.15; 0.33]

  1. CK Creatinine kinase, CRP C-reactive protein, PTH Parathyroid hormone, 25OHD 25-OH-Vitamin D, BAP Bone-specific alkaline phosphatase, OC Osteocalcin, P1NP N-terminal propeptide of type I collagen, CTX Cross-linked-C-telopeptide of type I collagen; median [quartiles]; a: normative values are given; b p<0.05; c: methotrexat (n = 2), azathioprine (n = 1), mycophenolatmofetil (n = 1), d: methotrexat (n = 5), mycophenolatmofetil (n = 2), clycophosphamide (n = 1), tacrolimus (n = 1)